Thu Apr 24 14:00:00 UTC 2025: ## Syngene International Stock Plummets 10% on Weak Q4 Results and Cautious FY26 Guidance

**MUMBAI, April 24, 2025** – Shares of Syngene International Ltd. experienced a sharp 10% decline today following the release of the company’s disappointing Q4 FY25 earnings report. The company reported a 3% year-on-year decrease in consolidated net profit to Rs 183 crore, down from Rs 189 crore in the same period last year. While total income increased to Rs 1,037 crore from Rs 933 crore, the profit dip and cautious outlook for FY26 spooked investors.

Syngene’s CFO, Deepak Jain, attributed the lower profit to an expected moderation in EBITDA margins to the mid-twenties and a year-on-year decline in profit after tax. The company’s FY26 revenue growth guidance of mid-single digits, significantly lower than market consensus of 15%, further fueled the sell-off. Brokerage notes cited concerns that FY26 revenue estimates may need to be slashed by 8-10%.

The weak performance comes after a tepid FY25, with only 2% constant currency and 4% INR revenue growth. The challenging global biotech funding environment also contributed to investor anxieties.

Despite the negative news, Syngene highlighted strategic initiatives, including the recent acquisition of a US-based biologics manufacturing facility, aimed at boosting its presence in the CDMO sector.

The drop in Syngene’s share price underscores the ongoing challenges facing the biotech industry. Investors are advised to consult with financial professionals before making any investment decisions.

Read More